Surrogate vs Patient-Important Outcomes
What a surrogate endpoint is, how it differs from outcomes patients feel or live with, and why a lab or scan change alone does not show a treatment helps.
Content last updated . This page has not been medically reviewed.
Plain definitions
- Clinical outcome (patient-important outcome). How a person feels, functions or survives. The FDA describes a surrogate endpoint as "a substitute for a direct measure of how a patient feels, functions, or survives." [1]
- Biomarker. A defined characteristic that is objectively measured as an indicator of normal processes, disease processes, or responses to an exposure or treatment. Some biomarkers are used as surrogate endpoints, but most are not. [1]
- Surrogate endpoint. A trial endpoint used in place of a direct measure of benefit. It does not measure the benefit itself; it is expected to predict it. [1]
- Clinical outcome assessment. A report from a clinician, patient or observer, or a performance test, that reflects how someone feels or functions. The FDA separates these from biomarkers. [1]
When a stand-in is trusted
The FDA describes three levels. A candidate surrogate is still being evaluated. A reasonably likely surrogate has a strong mechanistic or epidemiologic rationale but not enough clinical data; it can support the FDA's Accelerated Approval program, and more data are collected after approval. A validated surrogate is backed by a clear mechanism and clinical data showing that an effect on it predicts a specific benefit. [1]Blood pressure is the FDA's example of a validated surrogate: many trials of different blood-pressure medicines showed that lowering systolic pressure reduced stroke risk, so it can stand in for stroke in later trials. [1] Between 2010 and 2012 the FDA approved 45 percent of new drugs on the basis of a surrogate endpoint. [1] Trust is earned for a specific use, in a specific setting, not for a biomarker in general.
Why the gap matters
A treatment can move a surrogate without improving how people feel or live, or can carry side effects that the surrogate never shows. The FDA states that, before a surrogate is accepted, extensive evidence must accumulate, usually including clinical trials showing that the surrogate predicts clinical benefit. [1] Many products in emerging wellness science are described with biomarkers only: an inflammatory marker, a gut bacteria count, a "biological age" score, a brain-scan signal. Treat those as early signals, not proof of benefit.A quick way to check a claim
| Question | What to look for |
|---|---|
| What was actually measured? | A lab value or scan, or something the person experienced? |
| Is the stand-in validated? | Has an effect on it been shown, in trials, to predict a real benefit for this condition? |
| Was the real outcome also measured? | Symptoms, function, events or survival, not only the marker. |
| Who was studied, and for how long? | Short studies can show a marker move but cannot show long-term harm or benefit. |
Related guides
See biomarkers vs clinical outcomes for how markers are built and tested, surrogate endpoints and aging biomarkers in trials for the aging field, and clinical-trial phases explained. For decisions about your own care, talk with a clinician: talking with a health professional.Frequently asked questions
Is a surrogate endpoint the same as a biomarker?
No. Some surrogate endpoints are a small subset of biomarkers, but most biomarkers have not been shown to predict a clinical benefit. [1]
Does "FDA accepted a surrogate" mean the treatment is proven to help?
Not automatically. A validated surrogate is accepted as evidence of benefit, but a reasonably likely surrogate can support only an accelerated approval, with confirming data gathered afterward. [1]
Why use surrogates at all?
They are used when real outcomes like strokes take a very long time to study, when the surrogate is well understood, or when a clinical-outcome study would be unethical. [1]
Can I tell from a headline whether a marker matters?
Ask what changed in the person, not only in the test. If the report mentions only a marker, the claim is early-stage.